CYP cynata therapeutics limited

Ann: Publication comparing Cymerus MSCs to other MSCs, page-5

  1. 1,038 Posts.
    lightbulb Created with Sketch. 405
    The flaw in your logic is that it makes more sense to sit on GvHD until the Phase 2 results read-out. Why? Because between now and then, success is not a certainty. Retail investors, let alone big pharma, know and understand this.

    The consequence of a deal now would be a significantly lower upfront payment, probably contingent on the results, anyway. It is likely that milestone and/or royalties would also be lower. So why not wait, and if the results are good, negotiate from a position of power?

    Cynata's development has been a very slow burn, nearly 11 years since listing. I'm prepared to wait another 12-18 months if it means a GvHD deal will be more financially successful.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
16.0¢
Change
-0.010(5.88%)
Mkt cap ! $37.28M
Open High Low Value Volume
17.0¢ 17.0¢ 16.0¢ $28.98K 174.8K

Buyers (Bids)

No. Vol. Price($)
5 207290 15.5¢
 

Sellers (Offers)

Price($) Vol. No.
16.0¢ 11232 1
View Market Depth
Last trade - 14.34pm 31/07/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.